Teva Pharmaceutical Industries Limited Stock TEL AVIV STOCK EXCHANGE
Stocks
IL0006290147
Pharmaceuticals
OTC Markets Traded| Market Cap | 42.01B 127B 36.24B 34.09B 31.05B 58.4B 3,987B 58.71B 403B 157B 2,028B 158B 154B 6,725B | P/E 2026 * |
48.4x | P/E 2027 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 53.89B 163B 46.48B 43.72B 39.83B 74.91B 5,114B 75.31B 517B 201B 2,601B 202B 198B 8,626B | EV / Sales 2026 * |
3.25x | EV / Sales 2027 * | 2.93x |
| Free-Float |
88.59% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Teva Pharmaceutical Industries Limited
| 1 day | -3.96% |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 2022-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 2019-12-21 |
Matthew Shields
COO | Chief Operating Officer | 52 | 2024-06-02 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 2008-12-31 |
Sol Barer
CHM | Chairman | 78 | 2017-02-05 |
Rosemary Crane
BRD | Director/Board Member | 65 | 2015-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.96% | -6.73% | - | - | 42.01B | |
| +0.18% | -5.88% | +57.94% | +108.42% | 1,031B | |
| +1.72% | -0.97% | +51.91% | +68.55% | 641B | |
| +1.29% | -2.11% | +22.77% | +75.56% | 453B | |
| -1.50% | -7.04% | +33.55% | +33.94% | 349B | |
| +6.25% | +2.04% | +28.97% | +46.57% | 290B | |
| -0.07% | -4.12% | +0.95% | +11.79% | 252B | |
| +1.43% | -1.44% | +51.92% | +69.80% | 232B | |
| +0.51% | -4.52% | -19.50% | -54.83% | 201B | |
| +1.73% | +0.03% | +32.03% | +94.15% | 181B | |
| Average | +0.66% | -2.98% | +28.95% | +50.44% | 403.31B | |
| Weighted average by Cap. | +0.94% | -3.97% | +37.91% | +66.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.58B 50.12B 14.3B 13.45B 12.26B 23.05B 1,574B 23.18B 159B 61.91B 801B 62.26B 60.91B 2,654B | 17.3B 52.31B 14.93B 14.04B 12.79B 24.05B 1,642B 24.18B 166B 64.61B 835B 64.97B 63.56B 2,770B |
| Net income | 1.44B 4.36B 1.24B 1.17B 1.07B 2B 137B 2.01B 13.82B 5.38B 69.57B 5.41B 5.29B 231B | 2.69B 8.13B 2.32B 2.18B 1.99B 3.74B 255B 3.76B 25.79B 10.04B 130B 10.09B 9.87B 430B |
| Net Debt | 11.88B 35.9B 10.25B 9.64B 8.78B 16.51B 1,127B 16.6B 114B 44.35B 573B 44.59B 43.63B 1,901B | 8.61B 26.03B 7.43B 6.99B 6.37B 11.97B 817B 12.03B 82.6B 32.15B 416B 32.33B 31.63B 1,378B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
